Sonoma Pharmaceuticals (SNOA) Competitors $2.98 +0.06 (+2.05%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$2.98 0.00 (0.00%) As of 07/3/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. JATT, BIVI, QTTB, MTEX, CARM, BLRX, ERNA, AYTU, LGVN, and IMNNShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include JATT Acquisition (JATT), BioVie (BIVI), Q32 Bio (QTTB), Mannatech (MTEX), Carisma Therapeutics (CARM), BioLineRx (BLRX), Ernexa Therapeutics (ERNA), Aytu BioPharma (AYTU), Longeveron (LGVN), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors JATT Acquisition BioVie Q32 Bio Mannatech Carisma Therapeutics BioLineRx Ernexa Therapeutics Aytu BioPharma Longeveron Imunon JATT Acquisition (NYSE:JATT) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations. Does the media refer more to JATT or SNOA? In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score. Company Overall Sentiment JATT Acquisition Neutral Sonoma Pharmaceuticals Neutral Is JATT or SNOA more profitable? JATT Acquisition has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -24.23%. JATT Acquisition's return on equity of -49.58% beat Sonoma Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Sonoma Pharmaceuticals -24.23%-58.73%-21.05% Which has stronger valuation & earnings, JATT or SNOA? JATT Acquisition has higher earnings, but lower revenue than Sonoma Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ASonoma Pharmaceuticals$14.29M0.34-$3.46M-$3.10-0.96 Do insiders & institutionals have more ownership in JATT or SNOA? 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryJATT Acquisition beats Sonoma Pharmaceuticals on 6 of the 7 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.88M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-0.968.9827.5020.21Price / Sales0.34682.84421.02118.64Price / CashN/A158.5936.8958.07Price / Book1.094.588.045.67Net Income-$3.46M$31.34M$3.18B$249.13M7 Day Performance3.83%3.25%2.82%3.30%1 Month Performance-12.35%6.80%3.70%5.20%1 Year Performance969.63%1.89%35.41%21.38% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma PharmaceuticalsN/A$2.98+2.1%N/A+969.6%$4.88M$14.29M-0.96180Positive NewsJATTJATT AcquisitionN/A$1.13+1.8%N/A-67.3%$19.49MN/A0.003High Trading VolumeBIVIBioVie0.67 of 5 stars$1.01-1.9%$3.00+197.0%+131.4%$19.13MN/A-0.1310Gap DownQTTBQ32 Bio2.2333 of 5 stars$1.53-1.3%$12.17+695.2%-91.7%$18.91M$1.16M-0.3139MTEXMannatech0.2874 of 5 stars$9.42-3.9%N/A+37.8%$18.63M$117.87M-94.16250CARMCarisma Therapeutics1.9055 of 5 stars$0.45+2.2%$1.93+326.9%-70.8%$18.43M$19.63M-0.2920Gap UpHigh Trading VolumeBLRXBioLineRx2.7914 of 5 stars$4.00-5.7%$26.00+550.0%-78.2%$18.07M$28.94M-0.4540News CoveragePositive NewsERNAErnexa Therapeutics0.6656 of 5 stars$2.40-2.0%N/A-92.7%$18.04M$580K-0.2910Negative NewsAYTUAytu BioPharma3.7227 of 5 stars$1.98-1.0%N/A-13.7%$17.95M$81M-2.75160Analyst ForecastLGVNLongeveron3.3238 of 5 stars$1.15-4.2%$8.67+653.6%-20.3%$17.91M$2.39M-0.1820IMNNImunon2.4706 of 5 stars$0.92-9.6%$15.50+1,581.5%-34.1%$17.89M$500K-0.6830News Coverage Related Companies and Tools Related Companies JATT Acquisition Competitors BioVie Competitors Q32 Bio Competitors Mannatech Competitors Carisma Therapeutics Competitors BioLineRx Competitors Ernexa Therapeutics Competitors Aytu BioPharma Competitors Longeveron Competitors Imunon Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
